Novan (NASDAQ:NOVN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Novan (NASDAQ:NOVN) in a report released on Tuesday morning. The firm issued a sell rating on the stock.

Novan Price Performance

Shares of NOVN opened at $0.00 on Tuesday. Novan has a 52-week low of $0.08 and a 52-week high of $3.33. The firm has a market capitalization of $22,412.00, a price-to-earnings ratio of 0.00 and a beta of -0.06.

About Novan

Novan, Inc, a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases.